Oligo Modification By Application
May 4, 2026 / May 5, 2026 by Dawn Lam
Circular oligonucleotides are an emerging class of nucleic acid therapeutics (NATs) because of their resistance to exonucleases and their reduced immunogenicity.[1] Wesselhoeft et al., demonstrated that exogenous circRNA did not activate Toll-like Receptors (TLRs) nor Retinoic acid-Inducible Gene I (RIG-I), provided that the circRNA was meticulously purified to remove all linear RNA fragments. In addition, […]
Read more »
Tagged
Industry Insights Rare Disease
April 22, 2026 / April 23, 2026 by Dawn Lam
In May of 2025, a month after the last dose of k-abe was administered, a remarkable paper was published detailing the conception, development and treatment of the infant KJ Muldoon with an in vivo base editor to cure his carbamoyl-phosphate synthetase 1 (CPS1) deficiency.[1] CPS1 deficiency, which affects approximately 1 in 1,300,000 people, is a […]
March 23, 2026 / April 9, 2026 by Dawn Lam
Background Ligases are ubiquitous. They are found in every living organism and are required for cell division – stitching together the Okazaki fragments produced during DNA replication and maintaining genetic integrity by performing the final step in every DNA repair pathway – the crucial ligation step – which is the formation of a phosphodiester linkage […]
